PHYTOCHEMICAL ANALYSIS, ANTIOXIDANT AND HEPATOPROTECTIVE ACTIVITY OF ACTINIOPTERIS RADIATA

Objective: The medicinal plants have been using to treat ailments since ancient times. The recent advances in science and technology impel humans to evaluate medicinal plants therapeutic efficiency and isolation of bioactive compounds in pure forms before their use in development of new drugs and their derivatives. But even now, abundant medicinal plants unevaluated scientifically. The current study was aimed to explore phytochemical constituents, antioxidant and hepatoprotective activities of Actiniopteris radiata root parts. Methods: Standard procedures have been used to perform phytochemical analysis. Antioxidant activity was carried using In vitro methods on superoxide, hydroxyl, and 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radicals. Hepatoprotective activity was studied by paracetamol-induced liver toxicity on WISTAR albino rats. The parameters assessed were Aspartate aminotransferase (SGOT/AST), Alanine aminotransferase (SGPT/ALT), alkaline phosphatase (ALP) and total bilirubin levels. Results: The tested extracts (hexane, ethyl acetate, and hydro-alcoholic) possess biologically active compounds such as sterols, terpenoids, glycosides, phenolics, alkaloids, flavonoids. The hydro-alcoholic extract has more phenolic contents (24.28±0.3) and flavonoid contents (22.68±0.6). The extracts showed dose dependent activity on tested free radicals and extracts showed more percentage inhibition at 320µg. The hydro-alcoholic extract showed more percentage inhibition i.e. 71.00±2.08 on DPPH free radical, 79.67±1.20 on hydroxyl free radical and 80.33±1.20 on superoxide free radical. As antioxidant activity of hexane and ethyl acetate extracts was less and they also showed less percentage protection on liver toxicity, hydro-alcoholic extract showed more percentage protection on biomedical enzyme levels of liver toxicity at high concentration i.e., 400 mg/kg b.w. The percentage protection on the enhancement of AST (SGOT), ALT (SGPT), ALP, and total bilirubin levels were 82.24%, 82.14%, 84.18%, and 82.85% are significant (P<0.01) as Liv52 shown percentage protection on the enhancement of Aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT), Alkaline phosphatase (ALP) and total bilirubin levels were 93.58%, 92.83%, 94.67% and 93.57%. Conclusion: The current study was aimed to explore phytochemical constituents, antioxidant and hepatoprotective activities of Actiniopteris radiata root parts extracts. The outcome of the current research results provides scientific evidence of the traditional usage of Actiniopteris radiata

DESIGN, 23 FACTORIAL OPTIMIZATION AND IN VITRO–IN VIVO PHARMACOKINETIC EVALUATION OF ROSUVASTATIN CALCIUM LOADED POLYMERIC NANOPARTICLES

Objective: The objective is to incorporate low bioavailable Rosuvastatin Calcium (20%) into polymeric nanoparticles (PNs) to improve its biopharmaceutical properties of Rosuvastatin Calcium. Methods: The PNs were prepared by solvent evaporation method by applying 23 factorial designs. The formulated PN are investigated for particle size (PS) and shape, zeta potential (ZP), polydispersity index (PI) and entrapment efficiency (EE), in vivo pharmacokinetic. Results: Among 8 formulations, PN7 shows least PS of 159.9±16.1 nm, which enhance the dissolution, surface area and permeability; ZP of-33.5±1.54 mV, which shows good stability; PI of 0.587±0.16 shows monodisperse distribution pattern; high EE of about 94.20±2.46 %; percentage yield of 96.80±2.08 %; maximum in vitro drug release of about 96.54±2.02 % at 24 h with controlled and predetermined release pattern. PN7 drug release obeys zero-order release kinetics, non-fickian diffusion mechanism with r2 value>0.96 and release exponent ‘n’ value falls between 0.5-0.8 for peppas kinetic model i.e., the mechanism of drug diffusion is based on polymer relaxation. In vivo pharmacokinetic studies illustrate enhance in AUCo-α in mg/ml, which proves a significant enhancement of bioavailability of Rosuvastatin Calcium by PNs. Conclusion: This PN shows a significant enhancement of bioavailability by minimizing the dose-dependent adverse side effects of rosuvastatin calcium